ClinicalTrials.Veeva

Menu
A

Accellacare | Wilmington, Medical Center Drive

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Semaglutide
Tirzepatide
Cagrilintide
Metformin
Sugar
BI 456906
Ritlecitinib
AP01
Insulin icodec
SAR440340

Parent organization

This site is a part of Accellacare

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 21 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Enrolling
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Semaglutide

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine...

Enrolling
Obesity
Drug: Cagrilintide
Drug: Tirzepatide
Locations recently updated

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting
Obesity
Drug: Placebo cagrilintide
Drug: Cagrilintide
Locations recently updated

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk th...

Enrolling
Obesity
Drug: Semaglutide
Drug: Cagrilintide

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Progressive Pulmonary Fibrosis
Drug: AP01
Other: Placebo

The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pat...

Active, not recruiting
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: HD quadrivalent influenza vaccine
Biological: ExPEC9V

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have* a body mass index (BMI) of 30 kg/m² or more, or* a BMI of 27 kg/m² or more and a...

Active, not recruiting
Obesity
Drug: survodutide
Drug: Placebo

Primary Objective:Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

Trial sponsors

Novo Nordisk logo
Boehringer Ingelheim logo
Pfizer logo
A
I
Janssen (J&J Innovative Medicine) logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems